Scoop has an Ethical Paywall
Work smarter with a Pro licence Learn More

Video | Business Headlines | Internet | Science | Scientific Ethics | Technology | Search

 

Completion of a Clinical Study

26 September 2016

Christchurch Clinical Studies Trust Announces Completion of a Clinical Study

on Innovative Nicotine-Containing Product

Christchurch, New Zealand – 26 September 2016 – Christchurch Clinical Studies Trust Ltd today announces the completion of a clinical study on an innovative alternative to cigarettes.

The product prototype, designated “P3L” by the technology owner Philip Morris International, mixes nicotine with lactic acid to produce an inhalable nicotine salt aerosol with faster absorption rates than traditional nicotine replacement therapies. The device is the product of technology developed by Professor Jed Rose, co-inventor of the nicotine patch, and his colleagues at Duke University. Previously tested in Christchurch by Dr Chris Wynne and Dr Murray Laugesen, New Zealand’s leading public health specialist, the study validated the belief that P3L can provide smokers with a suitable alternative to smoking.

The study investigated nicotine absorption after a single use of the product by 16 adult smokers in comparison to the Nicorette® inhalator. Approximating the rapid nicotine absorption rates and levels of cigarettes is an important element of providing smokers with a satisfactory alternative to smoking. With P3L, nicotine absorption reached peak levels six times faster than with the inhalator, suggesting easier absorption and a significantly higher potential for acceptance by smokers. The study also assessed a range of subjective effects, as well as safety and tolerability. Compared with use of the inhalator, the study participants found the product a more satisfactory alternative and reported less intention to smoke cigarettes; no relevant side effects were reported.

Advertisement - scroll to continue reading

Are you getting our free newsletter?

Subscribe to Scoop’s 'The Catch Up' our free weekly newsletter sent to your inbox every Monday with stories from across our network.

Conducted in Christchurch, New Zealand, the study was approved by an Independent Ethics Committee, conducted in accordance with the principles of the Declaration of Helsinki, Guidance on Good Clinical Practice and in accordance with the Guideline on the Regulation of Therapeutic Products in New Zealand. The study was registered at www.clinicaltrials.gov (NCT02532374).

Principal study investigator Dr Chris Wynne, Medical Director at St Georges Cancer Care Centre, Christchurch, commented on the results:

“In addition to quitting, which remains the safest way to reduce the harm from smoking, a tobacco harm reduction strategy envisions the development of products with the potential to reduce individual risk compared to smoking. A critical element for acceptance by smokers is nicotine delivery similar to cigarettes as well as the rewarding of subjective effects, and this novel nicotine-containing product has proven to perform better than existing nicotine delivery systems in both areas.”

Given the promising results of this first clinical study, Christchurch Clinical Studies Trust Ltd will conduct further studies to assess in a larger population the potential for smokers to substitute cigarettes with the product.


ends

© Scoop Media

Advertisement - scroll to continue reading
 
 
 
Business Headlines | Sci-Tech Headlines

 
GenPro: General Practices Begin Issuing Clause 14 Notices

GenPro has been copied into a rising number of Clause 14 notices issued since the NZNO lodged its Primary Practice Pay Equity Claim against General Practice employers in December 2023.More

SPADA: Screen Industry Unites For Streaming Platform Regulation & Intellectual Property Protections

In an unprecedented international collaboration, representatives of screen producing organisations from around the world have released a joint statement.More

 
 
 
 
 
 
 
 
 
 
 
 

Join Our Free Newsletter

Subscribe to Scoop’s 'The Catch Up' our free weekly newsletter sent to your inbox every Monday with stories from across our network.